QuidelOrtho Q3 revenue misses estimates on soft respiratory season
QDEL•QuidelOrtho’s third-quarter revenue fell 12% year over year to $618.9 million, below the $628.13 million analyst estimate. The company reported adjusted diluted EPS of $0.31 and forecast 2026 revenue of $2.52 billion to $2.54 billion.
1. Quarterly results
QuidelOrtho said third-quarter revenue fell 12% year over year to $618.9 million, missing the $628.13 million analyst estimate. Adjusted diluted EPS was $0.31, while the company reported a net loss of $53.8 million and a loss per share of $0.78.
2. Revenue drivers and outlook
The company attributed lower Point of Care revenue to a weaker respiratory season and said lower Labs sales in China, tied to changes in In Vitro Diagnostics pricing, weighed on results. QuidelOrtho forecast 2026 revenue of $2.52 billion to $2.54 billion, adjusted EBITDA of $540 million to $545 million, and adjusted diluted EPS of $0.65 to $0.70. It also launched a cost transformation and restructuring program aimed at improving profitability.
